To evaluate the impact of three-dimensional transthoracic echocardiography on patient selection for percutaneous atrial septal defect repair.
Approach:
Study Design: A single-center retrospective analysis was conducted at Safra Children’s Hospital, Sheba Medical Center, Israel, from June 2021 through May 2024, focusing on the impact of three-dimensional transthoracic echocardiography on patient selection.
Key Findings:
36 patients aged 1–44 years were included in the study, with a median age of 6 years.
42% of patients were referred for surgical closure due to unsuitable anatomy for percutaneous intervention.
36% of patients underwent referral for three-dimensional transthoracic echocardiography after inconclusive initial imaging.
Interpretation:
Three-dimensional transthoracic echocardiography may assist in the selection of candidates for percutaneous closure without sedation, potentially improving patient outcomes.
Limitations:
The study was conducted at a single center, which may limit the generalizability of the findings.
The retrospective nature of the analysis may introduce selection bias.
Conclusion:
Three-dimensional transthoracic echocardiography provides valuable insights for selecting candidates for percutaneous atrial septal defect repair.
A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.
